Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;15(2):151-157.
doi: 10.5114/aic.2019.86010. Epub 2019 Jun 26.

Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts

Tomasz Roleder  1 , Elzbieta Pociask  2 , Wojciech Wanha  3 , Pawel Gasior  3 , Magdalena Dobrolinska  3 , Magdalena Garncarek  1 , Przemyslaw Pietraszewski  4 , Radoslaw Kurzelowski  3 , Grzegorz Smolka  3 , Wojciech Wojakowski  3
Affiliations

Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts

Tomasz Roleder et al. Postepy Kardiol Interwencyjnej. 2019.

Abstract

Introduction: There are no data presenting a serial assessment of vein graft healing after bioresorbable vascular scaffold (BVS) implantation at long-term follow-up.

Aim: To describe ABSORB BVS healing in vein grafts by optical coherence tomography (OCT) and high-definition intravascular imaging (HD-IVUS) at long-term follow-up.Material and methods: The study group consisted of 6 patients. The first patient had serial OCT assessment of BVS implanted in the saphenous vein grafts (SVG) at baseline and at 3-, 6-, 18-month follow-up and the second patient had OCT assessment of BVS implanted in the SVG at baseline and 24-, 48-month follow-up. The second and the third patients had OCT and HD-IVUS imaging at baseline and 48-month follow-up. The last 3 patients had OCT imaging of BVS implanted in the native coronary artery at 48-month follow-up.

Results: There were no differences in neointimal hyperplasia after BVS implantation between each time point. However, complete scaffold coverage was observed only 48 months after implantation. Out of 202 analyzed scaffold struts, there were 67 (33%) black boxes detectable at 48-month follow-up. HD-IVUS presented plaque burden up to 67% at the segment of BVS implantation at 48-months follow-up. There was a difference in neointimal hyperplasia thickness (1.27 (0.953-1.696) vs. 0.757 (0.633-0.848), p < 0.001) between a native coronary artery and BVS scaffolds at 48-month follow-up.

Conclusions: Bioresorbable vascular scaffold implanted in SVG characterized moderate neointimal hyperplasia as excessive as compared to native coronary arteries at long-term follow-up. The complete scaffold coverage was observed only 48 months after implantation.

Keywords: ABSORB; high-definition intravascular ultrasound; optical coherence tomography; vein graft.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study chart flow. The study chart flow presents the time of optical coherence tomography (OCT) and high definition intravascular (HD-IVUS) imaging of ABSORB implanted in vein grafts and coronary arteries HA – hypertension, HL – hyperlipidemia, DM – diabetes mellitus, CABG – coronary artery bypass grafting, GFR – glomerular filtration rate (ml/min/1.73 m2).
Figure 2
Figure 2
Representative serial OCT images of ABSORB implanted in vein graft. The figure presents OCT images of two bioresorbable vascular scaffolds (ABSORB) implanted in vein grafts at baseline, 3-, 6-, 18-, 24- and 40-month follow-up. The figure presents the measurements of neointimal thickness for every scaffolds strut. The two blue triangles present uncovered struts of ABSORB at 3-month follow-up
Figure 3
Figure 3
Representative angiography, OCT and HD-IVUS imaging of ABSORB implanted in the vein graft at 48-month follow-up. A – The coronary angiography presents the vein graft 48 months after ABSORB implantation. The dashed lines indicate (1, 2, 3) the position of HD-IVUS (B, D, F) and OCT cross-section images (C, E, G). The white arrows indicate the echogenic rim of the remaining neointima (B, D, F) and blue triangles indicate black boxes remaining (C, E, G) after ABSORB implantation
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899–907. - PubMed
    1. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010;6:447–53. - PubMed
    1. Naganuma T, Kawamoto H, Panoulas VF, et al. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. Int J Cardiol. 2017;246:26–31. - PubMed
    1. Gheorghe L, Millan X, Jimenez-Kockar M, et al. Bioresorbable Vascular Scaffolds in coronary chronic total occlusions. Clinical, vasomotor and optical coherence tomography findings at 3-year follow-up (ABSORB-CTO study) EuroIntervention. 2019;15:99–107. - PubMed
    1. Roleder T, Wanha W, Smolka G, et al. Bioresorbable vascular scaffolds in saphenous vein grafts (data from OCTOPUS registry) Postep Kardiol Inter. 2015;11:323–6. - PMC - PubMed